65,437 trials
Alopecia Areata
Primary: Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 — 30.65; 22.31; 23.39; 14.29 Percentage of…
Infertility
Primary: Ongoing Pregnancy Rate — 9; 4 Participants — p=0.10
Colon Malignant Tumor · Colon Benign Tumor
Primary: Successful Suture Approximation With Cinching Device — 3.57 score on a scale
Healthy Volunteers
Primary: Mean Beck Depression Inventory Score — 1.4; 1; 1.1 Units on a scale
COVID-19 · Hypoxia
Primary: Number of Participants With Adverse Events Related to High Dose Intravenous Vitamin C (HDIVC) — 0; 0 Participants
Asthma
Primary: Maximum Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Observed up to 2 Hours Following Completion of Dosing (FEV1max%0-2) at Day 22…
Renal Cell Carcinoma
Primary: Best Overall Response Rate — 5 percentage of participants
Xerostomia
Primary: Change in Dry Mouth Symptom by Visual Analog Scale at 14 Days From Baseline — 10.1; 11.6; 13.0 mm
Knee Osteoarthritis
Primary: Change From Baseline in WOMAC Pain Score at 26 Weeks (ITT Population) — -46.4; -46.6; -45.0 units on a scale — p=0.5874
Restless Legs Syndrome
Primary: Change in Augmentation Severity From Day 0 to Day 90 — 6.5; 0 score on a scale — p=0.0131
Tourette Syndrome
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 71 Participants
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events (AEs) — 0.0; 12.5; 12.5; 50.0 Percentage of participants (%)
Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Squamous Cell Carcinoma In Situ · Cervical Squamous Intraepithelial Neoplasia 2
Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…
Leukemia, Myeloid, Acute
Primary: Dose-limiting Toxicity — 0; 0 Participants
Surgery · Infection
Primary: The Number of Patients With Infections — 11; 10 Participants